Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects

Molecular Psychiatry

Volumn 7, Issue 2, 2002, Pages 157-164

  Crook, J M ^a   Akil, M ^a   Law, B C W ^a   Hyde, T M ^a   Kleinman, J E ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Brodmann's area 46; Glutamate neurotransmission; Immunocytochemistry; MGluR2 3; Western immunoblotting

Indexed keywords

GLUTAMIC ACID; METABOTROPIC RECEPTOR; PHENCYCLIDINE; PSYCHEDELIC AGENT;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BEHAVIOR DISORDER; BRAIN DYSFUNCTION; BRAIN REGION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LOCOMOTION; MALE; MAMMAL; NERVE CELL EXCITABILITY; NEUROBIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE HISTOCHEMISTRY; SCHIZOPHRENIA; TISSUE SPECIFICITY; WESTERN BLOTTING;

EID: 0036176446     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000966     Document Type: Article

References (52)

1. Anatomy and physiology of glutamate in the CNS
2. The glutamate synapse in neuropsychiatric disorders: Focus on schizophrenia and Alzheimer's disease
3. Amino acid transmitters
4. Glutamate: A neurotransmitter in mammalian brain
5. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy
6. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia
7. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional stereologic counting method
8. Development of the prefrontal cortex during adolescence: Insights into vulnerable neural circuits in schizophrenia
9. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: A possible neurochemical basis for 'hypofrontality'
10. The reduced neuropil hypothesis: A circuit based model of schizophrenia
11. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow (rCBF) evidence
12. A glutamatergic deficiency model of schizophrenia
13. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy
14. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
15. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
16. Recent advances in the phencyclidine model of schizophrenia
17. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
18. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis
19. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
20. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
21. Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory
22. The role of excitatory amino acids in prefrontal cortex function as assessed by spatial delayed alternation performance in rats: Modulation by dopamine
23. Excitatory amino acid antagonists and memory: Effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks
24. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
25. Presynaptic NMDA receptors display physiological characteristics of homomeric complexes of NRI subunits that contain the exon 5 insert in the N-terminal domain
26. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: Organization features related to cortical circuitry, function and disease
27. Characterization of a presynaptic glutamate receptor
28. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus
29. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia
30. The metabotropic glutamate receptors: Structure and functions
31. Function of metabotropic excitatory amino acid receptors in sensory transmission in the thalamus: Studies with novel phenyglycine antagonists
32. Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity
33. Metabotropic glutamate receptor activation and blockade: Their role in long-term potentiation, learning, and neurotoxicity
34. Pharmacology and functions of metabotropic glutamate receptors
35. Metabotropic G-protein-coupled glutamate receptors as therapeutic targets
36. Pharmacological agents acting at subtypes of metabotropic glutamate receptors
37. Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist
38. The metabotropic glutamate receptor types 2/3 inhibit L-type calcium channels via a pertussis toxin-sensitive G-protein in cultured cerebellar granule cells
39. Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death
40. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischemia
41. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations
42. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: II. Variability in locations of areas 9 and 46 and relationship to the talairach coordinate system
43. A versatile and simple method for staining nervous tissues using Giemsa dye
44. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
45. Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia
46. Localization of glutamate receptors in dorsal horn of rat spinal cord
47. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats
48. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations
49. The role of glutamate receptors in antipsychotic drug action
50. The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing
51. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat